Mendus

Mendus is dedicated to addressing the primary cause of cancer mortality—tumor recurrence—by developing dendritic cell-based immunotherapies. The company's lead asset, vididencel, has generated positive Phase 2 survival data in AML and is being prepared for pivotal development, marking a significant milestone. Mendus's strategy focuses on establishing its allogeneic cell platform as a foundational 'cancer maintenance' therapy and an intratumoral immune primer, targeting high-unmet-need indications like AML and ovarian cancer.

Allogeneic, off-the-shelf dendritic cell platform engineered ex vivo to present a broad repertoire of tumor antigens, enabling two therapeutic modalities: systemic maintenance therapy and intratumoral immune priming.

Mendus competes in the dendritic cell vaccine and intratumural therapy spaces. Its primary differentiation is its allogeneic, off-the-shelf platform focused on the maintenance therapy setting, offering scalability and a benign safety profile compared to autologous therapies and more toxic systemic drugs.